THERAPY DOSSIER · th-5c3e0e0a9407

Liposomal delivery of Foxm1 plasmid DNA

Other · Liposomal Foxm1 plasmid DNA; non-viral gene therapy.

Evidence & regulatory context

Mechanism: Liposomal Foxm1 plasmid DNA; non-viral gene therapy.
Target: Not recorded
Injury models: Endotoxin/LPS
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 31121134 ↗2019Reported benefit

Endothelial Hypoxia-Inducible Factor-1alpha Is Required for Vascular Repair and Resolution of Inflammatory Lung Injury through Forkhead Box Protein M1.

MouseEndotoxin/LPSEndothelial cell-restricted Hif1a disruption (Hif1a/Tie2Cre) mice and wild-type littermatesLiposomal delivery; specific route not stated in available textAfter sepsis challenge, during the recovery phase; exact timing not stated in a…

Model: Polymicrobial sepsis or endotoxaemia challenge causing inflammatory lung injury and endothelial barrier dysfunction

Endothelial-restricted loss of Hif1a caused defective vascular repair, persistent inflammation, reduced endothelial cell proliferation and increased mortality after sepsis or endotoxaemia, and therapeutic restoration of endothelial Foxm1 by liposomal plasmid delivery reactivated the vascular repair…

Extraction: extract · Supplied extraction confidence: 0.55. Machine-extracted fields require source verification.

Loading the evidence…